Animal models of antisense oligonucleotides: Lessons for use in humans

Molecular Medicine Today

Volumn 2, Issue 6, 1996, Pages 250-257

  Plenat, François ^a  

^a Laboratoire d'Histopathologie Moleculaire Experimentale BP 184 54505 ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

ANIMAL; EXPERIMENTAL ANIMAL; HUMAN; REVIEW;

ANIMALS; ANIMALS, LABORATORY; HUMANS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0030161385     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/1357-4310(96)88806-X     Document Type: Review

References (37)

1. Black, L.E. et al. (1994) Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies, Antisense Res. Dev. 4, 299-301
2. Helene, C. and Toulme, J.J. (1990) Specific regulation of gene expression by antisense, sense and anti-gene nucleic acid, Biochim. Biophys. Acta 1049, 99-125
3. Whitesell, L. et al. (1991) In vivo modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide, Antisense Res. Dev. 1, 349-350
4. Wahlestedt, C. (1994) Antisense oligonucleotide strategies in neuropharmacology, Trends Pharmacol. Sci. 15, 42-46
5. Tidd, D.M. and Warenius, H.M. (1989) Partial protection of oncogene, antisense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups, Br. J. Cancer 60, 343-360
6. Mesmaeker, A. et al. (1995) Antisense oligonucleotides, Acc. Chem. Res. 28, 366-374
7. Zendegui, J.G. et al. (1992) In vivo stability and kinetics of absorption and disposition of 3′ phosphopropyl amine oligonucleotides, Nucleic Acids Res. 20, 307-314
8. 3H-labelled oligonucleotides II. 3′,5′-blocked oligonucleotides, Antisense Res. Dev. 47, 636-646
9. Schwab, G. et al. (1994) Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice, Proc. Natl Acad. Sci. USA 91, 10460-10464
10. 14C-labelled phosphorothioate oligodeoxynucleotide, ISIS 2105, after intravenous administration to rats, J. Pharmacol. Exp. Ther. 267, 1181-1193
11. Crooke, S.T. (1995) Therapeutic Applications of Oligonucleotides, R.G. Landes & Co.
12. Offensperger, W.B. et al. (1993) In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotide, EMBO J. 12, 1257-1262
13. Stein, C.A. (1995) Does antisense exist? Nat. Med. 1, 1119-1121
14. Stein, C.A. and Krieg, A.M. (1994) Problems in interpretation of data derived from in vitro and in vivo use of antisense oligonucleotides. Antisense Res. Dev. 4, 67-69
15. Dean, M.N. and McKay, R. (1994) Inhibition of protein ase C-α expression in mice after systemic administration of phosphorate antisense oligodeoxynucleotides, Proc. Natl Acad. Sci. USA 91, 11762-6
16. Wahlestedt, C. et al. (1993) Antisense oligodeoxynucleotide NMDA-R1 receptor channel protect cortical neurons from excitotoxic and reduce focal ischaemic infarctions, Nature 363, 260-263
17. Sawai, K. et al. (1995) Renal disposition characteristics ofucleotides modified at terminal linkages in the perfused rat kidney, Antisen. Res. Dev. 5, 279-287
18. Agrawal, S. et al. (1991) Pharmacokinetics, biodistributioand stability of oligodeoxynucleotide phosphorothioates in mice, Proc. N Acad. Sci. USA 88, 7595-7599
19. 3H-labelled oligonucleotides I. Comparison of a phosphodiester ana phosphorothioate, Mol. Pharm. 45, 932-943
20. Iversen, P. (1991) In vivo studies with phosphorothioateonucleotides, pharmacokinetics prologue, Anti-cancer Drug. Des. 6, 531-53
21. 14C-labephosphorothioate oligonucleotide, ISIS 2105, after intradermal administrationrats, J. Pharmacol. Exp. Ther. 269, 89-94
22. Bricca, G. (1995) Sense, antisense, nonsense: where's the right way? J. Mol. Med. 73, 417-419
23. Chem, T.L. et al. (1993) Disposition and metabolism ofodeoxynucleotide methylphosphonate following a single intravenous injeion in mice. Drug Metab. Dispos. Biol. Fate Chem. 18, 815-818
24. Bayever, E. et al. (1993) Systemic administration ofhosphorothioate oligonucleotide with a sequence complementary to p53 focute myelogenous leukaemia and myelodysplatic syndrome: initial results of a Phase I trial, Antisense Res. Dev. 3, 383-390
25. Plenat, F. et al. (1995) Cell and tissue distribution of synth oligonucleotides in healthy and tumor-bearing nude mice. An autoradiographic, immunohistochemical, and direct fluorescence microscopy study. Am. J Path. 147, 124-135
26. Tan, T.M.C. and Ting, R.C.Y. (1995) In vitro and in vivo ibition of human papillomavirus type 15 E6 and E7 genes, Cancer Res. 55, 49-4605
27. Hijia, N. et al. (1994) Biologic and therapeutic significanceMYB expression in human melanoma, Proc. Natl Acad. Sci. USA 91, 4499-453
28. Higgins, K. et al. (1993) Antisense inhibition of the p65 subu of NF-κB blocks tumorigenicity and causes tumor regression, Proc. Natlcd. Sci. USA 90, 9901-9905
29. Wickstrom, E., Bacon, T.A. and Wickstrom, E.L. (1992) regulation of c-MYC antigen expression in lymphocytes of Eμ-c-myc tranenic mice treated with anti-c-myc DNA methylphosphonates, Cancer Res. 52, 41-6745
30. Gray, G.D. (1993) Antisense DNA inhibition of tumour growth induced by c-Ha-ras oncogene in nude mice, Cancer Res. 53, 577-580
31. Jain, R.K. (1990) Vascular and interstitial barriers to delivery of therapeutic agents in tumours, Cancer Metastasis Rev. 9, 253-266
32. Wilbo, D. et al. (1994) Antisense inhibition of hypertensiin the spontaneously hypertensive rat, Hypertension 25, 314-319
33. Guadette, M.F. et al. (1993) Effects on embryos of injection ofhosphorothioate oligonucleotides into pregnant mice, Antisense Res. Dev. 3, 396
34. Comish, K.G. et al. (1993) Cardiovascular effects of aosphorothioate oligonucleotide with sequence antisense to p53 in the consciorhesus monkey, Antisense Res. Dev. 3, 239-247
35. Galbraith, W.M. et al. (1994) Complement activation a hemodynamic changes following intravenous administration of phosphorhioate oligonucleotides in the monkey, Antisense Res. Dev. 4, 201-207
36. Branda, R.F. et al. (1993) Immune stimulation by antisense gomer complementary to the rev gene of HIV-1, Biochem. Pharm. 45, 2037-2043
37. Halpem, M.D. and Pisetsk,Y. (1995) In vitro inhibition of murine in feron γ production by phosphorothioate deoxyguanosine oligomers, Immunopharcology 29, 47-52